The RESHAPE-HF2 trial aimed to settle the debate initiated by the conflicting COAPT and MITRA-FR trials, however, it did not clarify the role of transcatheter edge-to-edge repair in heart failure.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 27%. Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, ...